NewAmsterdam Pharma (NASDAQ:NAMSW) Sees Large Growth in Short Interest

NewAmsterdam Pharma (NASDAQ:NAMSW) saw a large increase in short interest in May. As of May 29th, there was short interest totaling 71 shares, an increase of 69.0% from the May 14th total of 42 shares. Based on an average trading volume of 250 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On NewAmsterdam Pharma

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMSW traded up $2.18 during trading on Monday, hitting $20.98. The stock had a trading volume of 12,162 shares, compared to its average volume of 1,951. The firm has a 50 day moving average price of $22.76 and a 200 day moving average price of $22.83. NewAmsterdam Pharma has a twelve month low of $7.80 and a twelve month high of $30.45.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.